Introduction

KP Tissue, Inc. (TSX:KPT) is a Holding Company whose main asset is an approximately 12.0% interest in Kruger Products, one of Canada's largest tissue manufacturers and an expanding supplier in the United States. Kruger Products owns household brands including Cashmere, Purex, SpongeTowels and Scotties, produces private label tissue and serves commercial and institutional customers through its Away-From-Home division. KP Tissue funds its Dividend from distributions it receives from Kruger Products, so the payout ultimately depends on the operating company's cash generation, Capital spending and debt. Third quarter 2026 results, published on 11 November, showed higher Revenue and adjusted EBITDA, and the board declared another quarterly dividend of $0.21 per share, payable in January 2027. With a Dividend Yield of approximately 6.77%, investors are considering whether this income stream can hold steady as management warns of rising input costs, defers its next major mill decision and navigates a softer Canadian consumer environment.

Dividend Sustainability Analysis

Because KP Tissue owns only a minority stake in Kruger Products, its dividend capacity is determined by distributions declared at the operating level, where Kruger Inc. is the controlling shareholder. This structure passes cash directly to shareholders, but it leaves them reliant on decisions made by the operating partnership.

Recent operating performance has been encouraging. In the third quarter of 2026, Kruger Products reported revenue of about $590 million, up roughly 5% from a year earlier, and adjusted EBITDA of $93.5 million, an increase of about 9%. Lower pulp costs and better mill performance supported margins, and Net Income attributable to Kruger Products roughly doubled from the prior-year quarter.

Leverage remains the main area to monitor. Kruger Products carried debt, net of cash and excluding leases, of close to $1 billion at the end of September, although it also reported available Liquidity of more than $430 million. That combination is manageable for a consumer staples producer, but it limits flexibility if margins come under pressure.

It is also worth noting that Operating Cash Flow in the quarter was lower than a year earlier, and the 2026 increase in the Cash Dividend to $0.21 per quarter was tied to a change in the dividend's tax designation from eligible to non-eligible rather than to a step change in earnings. Overall, the dividend appears supported by improved profitability, although its Margin of safety depends on cost control and capital discipline.

Dividend Outlook

The dividend outlook appears stable, with limited scope for growth beyond the 2026 adjustment. KP Tissue has a long record of maintaining its quarterly payout through varied operating conditions, reflecting the essential nature of tissue demand.

Management expects fourth quarter adjusted EBITDA to be slightly below the third quarter but above the same period of 2025, assuming the current Tariff environment persists. That guidance suggests continued Earnings support for distributions, though momentum may moderate as costs rise.

Management has also flagged escalating input costs and inflationary pressure, and is weighing productivity initiatives and pricing actions in response. If those measures fall short or Canadian softness continues, distribution growth would likely pause, so the outlook favours stability over meaningful increases.

Key Growth Drivers

KP Tissue benefits from several structural growth drivers that could support long-term Shareholder value. The most significant is Kruger Products' growth in the United States, where consumer and Away-From-Home volumes have helped offset softer conditions in Canada.

Premium through-air-dried tissue capacity remains a long-term opportunity. Kruger Products continues to evaluate a new TAD Facility in the western United States, although the site decision has been deferred and management now expects the project will not begin operations in 2028, pushing that growth further out.

Operational efficiency is another driver. Improved mill performance and the ramp-up of U.S. converting capacity have contributed to recent margin expansion and could support further productivity gains.

Brand strength in Canada underpins pricing power. Cashmere, Purex and SpongeTowels are among the country's best-known household brands, and management is investing to recover Market Share lost to consumer trade-down.

Pricing and productivity actions may help protect margins as input costs rise, allowing Kruger Products to pass through part of its cost increases over time.

Finally, the defensive nature of tissue Demand supports long-term stability, as household and commercial consumption tends to remain steady across economic cycles.

Potential Catalysts

Several catalysts could shape returns over the coming quarters. Fourth quarter results in line with management's outlook would confirm that recent margin gains are durable despite rising costs.

Successful implementation of pricing increases and productivity initiatives could offset inflationary pressure and protect cash flow.

A clear decision on the western U.S. TAD facility, including financing and expected returns, would provide visibility on the next phase of growth.

Gradual deleveraging at Kruger Products would improve financial flexibility and reduce risk to distributions.

Progress on the Canadian share recovery plan could restore domestic Volume growth and strengthen the Brand portfolio.

Key Risks to Consider

Despite its defensive profile, KP Tissue carries several risks that investors should consider. Input cost Inflation is a primary concern, as management has signalled escalating costs and pulp prices can rise quickly from current levels.

Dependence on Kruger Products is significant. KP Tissue holds a minority interest and has limited influence over capital allocation, distribution policy or strategic direction.

Leverage and capital intensity could become burdensome if a large greenfield TAD project proceeds while margins weaken.

Competition from private label products and larger global tissue producers can restrict pricing power, particularly when consumers trade down.

Trade and currency exposure matters as U.S. operations grow. Tariff changes and movements in the Canadian dollar can affect costs, pricing and reported results.

Energy, freight and labour costs can also weigh on margins, and the decline in operating cash flow during the third quarter shows that cash generation can vary from quarter to quarter.

Valuation Perspective

KP Tissue is best assessed using Enterprise value to EBITDA for Kruger Products, free cash flow after capital spending, Leverage and dividend yield, rather than KP Tissue's own reported earnings, which reflect its Equity accounting structure.

A dividend yield of approximately 6.77% is notable for a consumer staples business, though part of that premium reflects the holding company structure, the minority position, leverage and exposure to pulp and other input costs.

The valuation case strengthens if margin improvements prove durable and capital projects generate attractive returns. Conversely, persistent cost inflation or an expensive expansion programme could keep the shares at a discount.

Technical Analysis and Key Levels

From a technical standpoint, investors may watch whether the shares sustain a pattern of higher lows, using the 50-day and 200-day moving averages as gauges of medium- and long-term trend direction.

Rising volume on advances following quarterly results or TAD project updates would indicate firmer demand. Failures near prior resistance on declining volume, particularly as cost pressures build, could suggest fading momentum.

Long-term income investors typically place greater weight on distribution coverage and leverage trends than on short-term price fluctuations.

Investment Outlook

KP Tissue, Inc. provides indirect exposure to Kruger Products, a leading Canadian tissue maker with expanding U.S. operations and widely recognized household brands. Third quarter 2026 results showed higher revenue and adjusted EBITDA, supported by lower pulp costs and better mill performance, and the board has continued to declare a quarterly dividend of $0.21 per share. The 2026 increase in the cash dividend reflects a tax designation change rather than a fundamental shift, so sustainability is best judged on Kruger Products' cash generation and leverage. Management expects a modest sequential dip in fourth quarter earnings and rising input costs, while the western U.S. TAD facility has been delayed beyond earlier timelines. Key risks include cost inflation, leverage near $1 billion, minority ownership and Canadian market softness. For income investors seeking consumer staples exposure, KP Tissue offers a defensive profile, with future returns depending on margin durability, disciplined capital allocation and continued U.S. growth.